Annual CFI
-$293.50 M
-$302.71 M-3287.12%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual cash flow from investing activities is currently -$293.50 million, with the most recent change of -$302.71 million (-3287.12%) on 31 December 2023. During the last 3 years, it has fallen by -$288.49 million (-5757.15%). CPRX annual CFI is now -888.45% below its all-time high of $37.23 million, reached on 31 December 2019.CPRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$259.00 K
-$249.00 K-2490.00%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly cash flow from investing activities is currently -$259.00 thousand, with the most recent change of -$249.00 thousand (-2490.00%) on 30 September 2024. Over the past year, it has increased by +$92.56 million (+99.72%). CPRX quarterly CFI is now -100.82% below its all-time high of $31.66 million, reached on 31 December 2019.CPRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$38.79 M
+$92.56 M+70.47%
30 September 2024
Summary:
Catalyst Pharmaceuticals TTM cash flow from investing activities is currently -$38.79 million, with the most recent change of +$92.56 million (+70.47%) on 30 September 2024. Over the past year, it has increased by +$216.40 million (+84.80%). CPRX TTM CFI is now -193.00% below its all-time high of $41.71 million, reached on 30 June 2020.CPRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3287.1% | +99.7% | +84.8% |
| 3 y3 years | -5757.1% | -280.9% | -253.2% |
| 5 y5 years | -1845.9% | -105.1% | -296.8% |
CPRX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -3287.1% | at low | -102.8% | +99.8% | -520.1% | +86.8% |
| 5 y | 5 years | -888.5% | at low | -100.8% | +99.8% | -193.0% | +86.8% |
| alltime | all time | -888.5% | at low | -100.8% | +99.8% | -193.0% | +86.8% |
Catalyst Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$259.00 K(+2490.0%) | -$38.79 M(-70.5%) |
| June 2024 | - | -$10.00 K(-95.0%) | -$131.34 M(+0.0%) |
| Mar 2024 | - | -$199.00 K(-99.5%) | -$131.33 M(-55.3%) |
| Dec 2023 | -$293.50 M(-3287.1%) | -$38.32 M(-58.7%) | -$293.50 M(+15.0%) |
| Sept 2023 | - | -$92.82 M(<-9900.0%) | -$255.18 M(+57.0%) |
| June 2023 | - | $0.00(-100.0%) | -$162.50 M(+6.1%) |
| Mar 2023 | - | -$162.37 M(<-9900.0%) | -$153.16 M(-1763.1%) |
| Dec 2022 | $9.21 M(-183.6%) | $0.00(-100.0%) | $9.21 M(+0.4%) |
| Sept 2022 | - | -$132.00 K(-101.4%) | $9.17 M(-0.7%) |
| June 2022 | - | $9.34 M(>+9900.0%) | $9.23 M(-324.6%) |
| Mar 2022 | - | $0.00(-100.0%) | -$4.11 M(-62.7%) |
| Dec 2021 | -$11.02 M(+119.9%) | -$41.00 K(-39.7%) | -$11.02 M(+0.4%) |
| Sept 2021 | - | -$68.00 K(-98.3%) | -$10.98 M(-47.5%) |
| June 2021 | - | -$4.00 M(-42.1%) | -$20.92 M(+23.6%) |
| Mar 2021 | - | -$6.91 M(<-9900.0%) | -$16.92 M(+237.7%) |
| Dec 2020 | -$5.01 M(-113.5%) | $0.00(-100.0%) | -$5.01 M(-118.8%) |
| Sept 2020 | - | -$10.01 M(<-9900.0%) | $26.65 M(-36.1%) |
| June 2020 | - | $0.00(-100.0%) | $41.71 M(+31.3%) |
| Mar 2020 | - | $5.00 M(-84.2%) | $31.78 M(-14.6%) |
| Dec 2019 | $37.23 M(-346.8%) | $31.66 M(+527.3%) | $37.23 M(+88.9%) |
| Sept 2019 | - | $5.05 M(-150.8%) | $19.71 M(-11.4%) |
| June 2019 | - | -$9.93 M(-195.0%) | $22.24 M(-18.3%) |
| Mar 2019 | - | $10.45 M(-26.1%) | $27.21 M(-280.4%) |
| Dec 2018 | -$15.08 M(>+9900.0%) | $14.14 M(+86.7%) | -$15.08 M(-48.3%) |
| Sept 2018 | - | $7.58 M(-252.9%) | -$29.17 M(-20.7%) |
| June 2018 | - | -$4.96 M(-84.4%) | -$36.77 M(+15.6%) |
| Mar 2018 | - | -$31.85 M(<-9900.0%) | -$31.82 M(>+9900.0%) |
| Dec 2017 | -$4000.00(-100.1%) | $60.80 K(-304.0%) | -$3900.00(-100.7%) |
| Sept 2017 | - | -$29.80 K(+1555.6%) | $521.80 K(-81.0%) |
| June 2017 | - | -$1800.00(-94.6%) | $2.75 M(-23.3%) |
| Mar 2017 | - | -$33.10 K(-105.6%) | $3.59 M(+0.9%) |
| Dec 2016 | $3.55 M(<-9900.0%) | $586.50 K(-73.3%) | $3.55 M(+17.8%) |
| Sept 2016 | - | $2.20 M(+164.1%) | $3.02 M(+290.1%) |
| June 2016 | - | $832.70 K(-1369.4%) | $773.20 K(-2784.7%) |
| Mar 2016 | - | -$65.60 K(-229.9%) | -$28.80 K(+343.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | -$6500.00(-99.9%) | $50.50 K(-213.7%) | -$6500.00(-90.1%) |
| Sept 2015 | - | -$44.40 K(-244.6%) | -$65.90 K(+929.7%) |
| June 2015 | - | $30.70 K(-170.9%) | -$6400.00(-99.9%) |
| Mar 2015 | - | -$43.30 K(+386.5%) | -$10.05 M(+15.0%) |
| Dec 2014 | -$8.74 M(+16.6%) | -$8900.00(-158.9%) | -$8.74 M(-43.7%) |
| Sept 2014 | - | $15.10 K(-100.2%) | -$15.54 M(-21.3%) |
| June 2014 | - | -$10.01 M(-891.5%) | -$19.75 M(+155.9%) |
| Mar 2014 | - | $1.26 M(-118.6%) | -$7.72 M(+2.9%) |
| Dec 2013 | -$7.50 M(-46.7%) | -$6.81 M(+62.2%) | -$7.50 M(-49.2%) |
| Sept 2013 | - | -$4.20 M(-307.6%) | -$14.74 M(+39.8%) |
| June 2013 | - | $2.02 M(+36.1%) | -$10.55 M(-16.1%) |
| Mar 2013 | - | $1.49 M(-110.6%) | -$12.57 M(-10.6%) |
| Dec 2012 | -$14.06 M(>+9900.0%) | -$14.05 M(<-9900.0%) | -$14.06 M(-804.7%) |
| Sept 2012 | - | $0.00(-100.0%) | $2.00 M(+0.1%) |
| June 2012 | - | -$1900.00(-62.0%) | $1.99 M(<-9900.0%) |
| Mar 2012 | - | -$5000.00(-100.2%) | -$8600.00(+138.9%) |
| Dec 2011 | -$3600.00(+24.1%) | $2.00 M(<-9900.0%) | -$3600.00(-99.8%) |
| Sept 2011 | - | -$2000.00(-99.9%) | -$2.01 M(+0.1%) |
| June 2011 | - | -$2.00 M(<-9900.0%) | -$2.01 M(>+9900.0%) |
| Mar 2011 | - | $0.00(-100.0%) | -$2900.00(0.0%) |
| Dec 2010 | -$2900.00(+26.1%) | -$2900.00(<-9900.0%) | -$2900.00(+26.1%) |
| Sept 2010 | - | $0.00(0.0%) | -$2300.00(0.0%) |
| June 2010 | - | $0.00(-100.0%) | -$2300.00(0.0%) |
| Dec 2009 | -$2300.00(+76.9%) | -$2300.00(<-9900.0%) | -$2300.00(<-9900.0%) |
| Sept 2009 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2008 | -$1300.00(-98.0%) | $0.00(0.0%) | -$1300.00(-88.4%) |
| Sept 2008 | - | $0.00(0.0%) | -$11.20 K(-66.2%) |
| June 2008 | - | $0.00(-100.0%) | -$33.10 K(-47.5%) |
| Mar 2008 | - | -$1300.00(-86.9%) | -$63.10 K(-4.2%) |
| Dec 2007 | -$65.90 K(+212.3%) | -$9900.00(-54.8%) | -$65.90 K(+17.7%) |
| Sept 2007 | - | -$21.90 K(-27.0%) | -$56.00 K(+64.2%) |
| June 2007 | - | -$30.00 K(+631.7%) | -$34.10 K(+731.7%) |
| Mar 2007 | - | -$4100.00 | -$4100.00 |
| Dec 2006 | -$21.10 K(+441.0%) | - | - |
| Dec 2005 | -$3900.00(+116.7%) | - | - |
| Dec 2004 | -$1800.00 | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual CFI year-on-year change?
- What is Catalyst Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly CFI year-on-year change?
- What is Catalyst Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM CFI year-on-year change?
What is Catalyst Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of CPRX is -$293.50 M
What is the all time high annual CFI for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual cash flow from investing activities is $37.23 M
What is Catalyst Pharmaceuticals annual CFI year-on-year change?
Over the past year, CPRX annual cash flow from investing activities has changed by -$302.71 M (-3287.12%)
What is Catalyst Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of CPRX is -$259.00 K
What is the all time high quarterly CFI for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly cash flow from investing activities is $31.66 M
What is Catalyst Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, CPRX quarterly cash flow from investing activities has changed by +$92.56 M (+99.72%)
What is Catalyst Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of CPRX is -$38.79 M
What is the all time high TTM CFI for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM cash flow from investing activities is $41.71 M
What is Catalyst Pharmaceuticals TTM CFI year-on-year change?
Over the past year, CPRX TTM cash flow from investing activities has changed by +$216.40 M (+84.80%)